Skip to market wire
Back to Market返回行情

LLY Eli Lilly and Company

USHealthcare
$1,247.64-0.62%ClosedMarket Cap: $1.17T

As of 2026-08-24

Why LLY matters now

Eli Lilly and Company (LLY) is a US stock in Healthcare. The latest InvestLog snapshot shows $1,247.64 with -0.62% on the session and $1.17T in market capitalization; recent performance reads 1-month +7.51% and YTD +2.18%.

The latest financial table shown here is Q1 2026, with revenue of $19.80B, net income of $7.40B, and EPS of $8.26. Investors can compare that operating picture with valuation signals such as P/E 43.01 and FCF yield 1.3%.

InvestLog's latest related AI research is a Options Activity note titled "LLY options: estimated premium turnover $84M; largest line LLY260918C01220000 (Call) $6M (expires 2026-09-18)". The latest indexable market news headline is "Eli Lilly Slips as Its $1.1 Trillion Valuation Cools" from GuruFocus.

Additional event context on this page matters because analyst consensus is Buy with a median target of $1,280.00; recent insider activity includes Alvarez Ralph filing A-Award; recent congressional disclosure data includes Byron Donalds Purchase. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

43.01

PEG

0.45

P/B

31.49

P/S

14.31

EV/EBITDA

32.05

DCF Value

$497.85

FCF Yield

1.3%

Div Yield

0.6%

Margins & Returns

Gross Margin

83.5%

Operating Margin

45.9%

Net Margin

35.0%

ROE

101.3%

ROA

21.7%

ROIC

32.1%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$19.80B$7.40B$8.26
Q4 2025$19.29B$6.64B$7.39
FY 2025$65.18B$20.64B$22.95
Q3 2025$17.60B$5.58B$6.21

Analyst Ratings

Consensus

Buy

Target (Consensus)

$1,271.24

Target (Median)

$1,280.00

Target Range

$1,119.00 - $1,400.00

Strong Buy: 6Buy: 18Hold: 5Sell: 1Strong Sell: 1
JefferiesBuy
2026-06-09
B of A SecuritiesBuy
2026-05-26
BarclaysOverweight
2026-05-05
GuggenheimBuy
2026-05-05
Wolfe ResearchOutperform
2026-05-04

Trading Activity

Insider Trades

Alvarez Ralphdirector
Sell2026-06-16
Fyrwald J Erikdirector
Sell2026-06-16
LUCIANO JUAN Rdirector
Sell2026-06-16
Sulzberger Gabrielledirector
Sell2026-06-16
Yuffa Ilyaofficer: EVP&Pres, LLY USA&Global Capab
Sell2026-06-11

Congress Trades

Byron DonaldsBuy
2026-05-14
Gilbert CisnerosBuy
2026-05-11
Lizzie FletcherSell
2026-05-01
Gilbert CisnerosSell
2026-04-08
Angus KingSell
2026-03-24

Related AI Research

Options ActivityAug 24, 2026

LLY options: estimated premium turnover $84M; largest line LLY260918C01220000 (Call) $6M (expires 2026-09-18)LLY 期权异动:所扫描合约成交权利金估算约 $84M;最大合约 LLY260918C01220000(看涨期权 Call)约 $6M(2026-09-18 到期)

Estimated premium turnover across the scanned LLY contracts was $84M on 22,645 contracts. The call/put volume ratio was 2.1x (calls 15,302 / puts 7,343).LLY 所扫描合约权利金成交额估算为 $84M,成交量 22,645 张;Call/Put 成交量比为 2.1x(Call 15,302 张 / Put 7,343 张)。最大合约为 LLY260918C01220000(看涨期权 Call),权利金成交额估算 $6M,到期日 2026-09-18。

Material Company EventAug 24, 2026

LLY regulated product launch: Eli Lilly Launches Foundayo Weight-Loss Pill in U.K.Eli Lilly and Company(LLY)正式推出获批药品或治疗产品

LLY regulated product launch: Eli Lilly Launches Foundayo Weight-Loss Pill in U.K.. WSJ published the event on 2026-08-24.Eli Lilly and Company(LLY)正式推出获批药品或治疗产品。WSJ 于 2026-08-24 发布该事件。

Options ActivityAug 17, 2026

LLY options: estimated premium turnover $57M; largest line LLY260918C01080000 $5M (expires 2026-09-18)LLY 期权异动:所扫描合约成交权利金估算约 $57M;最大合约 LLY260918C01080000 约 $5M(2026-09-18 到期)

On August 17, 2026, Eli Lilly (LLY) posted $57.04 million in listed option notional turnover across 23,935 total contracts, equal to 2.7% of the underlying stock’s daily dollar volume.2026年8月17日礼来(LLY)的期权成交细节如下:总成交名义金额5703.7万美元,共23935张合约,占当日股票成交量的2.7%;近价内期权窗口内有1164份合约,最近到期日为2026年8月21日。看涨期权成交量14238张,看跌期权9697张,看涨看跌比1.47。

Company Info

Sector

Healthcare

Industry

Drug Manufacturers - General

Country

US

Exchange

Beta

0.52

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.